Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma

BACKGROUND: [(99m)Tc]Tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification. Two nearly identical nonrandomized phase III trials compared [(99m)Tc]tilmanocept to vital blue dye. METHODS: Patients received [(99m)Tc]tilmanocept and blue dye....

Descripción completa

Detalles Bibliográficos
Autores principales: Sondak, Vernon K., King, Dennis W., Zager, Jonathan S., Schneebaum, Schlomo, Kim, Julian, Leong, Stanley P. L., Faries, Mark B., Averbook, Bruce J., Martinez, Steve R., Puleo, Christopher A., Messina, Jane L., Christman, Lori, Wallace, Anne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Melanomas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560941/
https://www.ncbi.nlm.nih.gov/pubmed/23054107
http://dx.doi.org/10.1245/s10434-012-2612-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560941/
https://www.ncbi.nlm.nih.gov/pubmed/23054107
http://dx.doi.org/10.1245/s10434-012-2612-z

Ejemplares similares